Adage Capital Partners
KTTA icon

Adage Capital Partners’s Pasithea Therapeutics KTTA Stock Holding History

Adage Capital Partners’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Hold
2,100,000
– – ﹤0.01% 894
2026
Q1 		$1.56M Hold
2,100,000
– – ﹤0.01% 853
2025
Q4 		$2.71M Buy
+2,100,000
New +$1.85M ﹤0.01% 817

Other funds holding KTTA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Adage Capital Partners's KTTA Position: Q2 2026 in Review

Adage Capital Partners held its Pasithea Therapeutics (KTTA) position steady in Q2 2026 at 2,100,000 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #894.

Adage Capital Partners first reported a position in KTTA in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.71M in Q4 2025. 25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Adage Capital Partners held 2,100,000 shares of Pasithea Therapeutics worth $1.08M as of Q2 2026.
  • Adage Capital Partners left its Pasithea Therapeutics share count unchanged in Q2 2026.
  • Pasithea Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #894 holding.
  • Adage Capital Partners first reported a position in Pasithea Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Adage Capital Partners's Pasithea Therapeutics position peaked at $2.71M in Q4 2025.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.